D. Birle

发表

Protein tyrosine phosphatases.

A. Alonso, N. Bottini, T. Mustelin, 2002, Frontiers in bioscience : a journal and virtual library.

The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling

T. Mustelin, D. Birle, D. Mercola, 2001, Nature Cell Biology.

Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts

D. Birle, D. Hedley, 2006, Molecular Cancer Therapeutics.

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors.

L. C. Chen, J. Baselga, D. Birle, 2012 .

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors.

L. C. Chen, J. Baselga, D. Birle, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Negative Feedback Regulation of the Tumor Suppressor PTEN by Phosphoinositide-Induced Serine Phosphorylation1

N. Bottini, T. Mustelin, D. Birle, 2002, The Journal of Immunology.

Phosphoinositide-Induced Serine Suppressor PTEN by Negative Feedback Regulation of the Tumor

N. Bottini, T. Mustelin, D. Birle, 2002 .

Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas.

D. Birle, D. Hedley, A. Fyles, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Trialwith Pharmacodynamic Endpoints of the Proteasome Inhibitor Bortezomib in PatientswithMetastatic Colorectal Cancer

A. Oza, D. Birle, D. Hedley, 2005 .

Up-regulation of the redox mediators thioredoxin and apurinic/apyrimidinic excision (APE)/Ref-1 in hypoxic microregions of invasive cervical carcinomas, mapped using multispectral, wide-field fluorescence image analysis.

D. Birle, D. Hedley, T. Nicklee, 2004, The American journal of pathology.

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

G. Pond, A. Oza, D. Birle, 2006, British Journal of Cancer.

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

Jordi Rodon, Diana Birle, J. Baselga, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.

I. Tannock, D. Birle, Licun Wu, 2005, Cancer research.

A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors.

J. Baselga, D. Birle, D. Demanse, 2010 .

Negative Feedback Regulation of the Tumor

Nunzio Bottini, Tomas Mustelin, Eileen D. Adamson, 2013 .

A Phase II Trial with Pharmacodynamic Endpoints of the Proteasome Inhibitor Bortezomib in Patients with Metastatic Colorectal Cancer

H. Mackay, A. Oza, D. Birle, 2005, Clinical Cancer Research.

Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors.

D. Birle, D. Hedley, 2007, Cancer research.

Protein tyrosine phosphatases.

A. Alonso, N. Bottini, T. Mustelin, 2002, Frontiers in bioscience : a journal and virtual library.

Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.

I. Tannock, D. Birle, Licun Wu, 2005, Cancer research.

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

G. Pond, A. Oza, D. Birle, 2006, British Journal of Cancer.